# **Special Issue**

# Precision Medicine in Neurodegenerative Disorders: Diagnosis, Treatment, and Management

# Message from the Guest Editor

Neurodegenerative disorders are characterized by progressive neuronal loss in the central nervous system, causing a decline in nervous system function. Precision medicine (PM) is a course of treatment tailored specifically to an individual patient or subpopulation based on a particular genotype or specific biomarkers that could be indicative of the course of the disorder. Precision medicine uses novel biomarkers, targetable disease mechanisms, pharmacogenomics, and pharmacogenetics for early diagnosis, appropriate treatment selection, tracking response to therapy, progression, and prognosis. Its role in the diagnosis, management, monitoring, and prognosis of diseases has become more important in recent years due to the augmentation of the -omics fields, such as proteomics, metabolomics, genomics, and transcriptomics, which have allowed for PM to establish reliability as a developing domain. The use of novel biomarkers in neurodegenerative diseases has allowed for individualized therapies and prognoses to be more prevalent, increasing the accuracy of diagnoses and the efficacy of interventions based on PM.

#### **Guest Editor**

Dr. Georgia Xiromerisiou

Institute of Preventive Neurology and Brain Helath, Thessaloniki, Greece

### Deadline for manuscript submissions

closed (31 March 2022)



# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/65240

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

## Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

